⁶⁴Cu-based radiopharmaceuticals
Intractable cancers
PreclinicalActive
Key Facts
About LinqMed
Japanese radiopharmaceutical startup developing copper-64-based theranostic agents for visible cancer diagnosis and treatment.
View full company profileIntractable cancers
Japanese radiopharmaceutical startup developing copper-64-based theranostic agents for visible cancer diagnosis and treatment.
View full company profile